Current developments of macrophage migration inhibitory factor (MIF) inhibitors.

The cytokine macrophage migration inhibitory factor (MIF) is regarded as a major regulator of inflammation and a key mediator that counter-regulates the inhibitory effects of glucocorticoids within the immune system. Therefore, MIF is a therapeutic target for the treatment of inflammatory and autoimmune diseases. In addition, MIF was found to be implicated in cancer pathogenesis. Current therapeutic strategies for targeting MIF focus on inhibiting its signaling activity by small molecules or modulating its biological activities using anti-MIF neutralizing antibodies. In this review, the structure and biological functions of MIF are briefly outlined. Then, the available inhibitors of MIF are systematically summarized. Finally, the recent advances that have been made in the computer-aided drug design and molecular modeling studies of MIF are reviewed.

[1]  Y. Hishikawa,et al.  Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma , 2005, Cancer.

[2]  J. Bernhagen,et al.  Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Bernhagen,et al.  The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. , 2007, Molecular endocrinology.

[4]  Jackeline Agorreta,et al.  microRNA-451 Regulates Macrophage Migration Inhibitory Factor Production and Proliferation of Gastrointestinal Cancer Cells , 2009, Clinical Cancer Research.

[5]  J. Bernhagen,et al.  Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. , 2002, Microbes and infection.

[6]  Tina Peng,et al.  Sustained Mitogen-activated Protein Kinase (MAPK) and Cytoplasmic Phospholipase A2 Activation by Macrophage Migration Inhibitory Factor (MIF) , 1999, The Journal of Biological Chemistry.

[7]  A. Koong,et al.  Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. , 2007, Cancer research.

[8]  S. Onodera,et al.  High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. , 1999, Cytokine.

[9]  S. Yamamoto,et al.  Coumarin and chromen-4-one analogues as tautomerase inhibitors of macrophage migration inhibitory factor: discovery and X-ray crystallography. , 2001, Journal of medicinal chemistry.

[10]  K. Iczkowski,et al.  Inhibition of Macrophage Migration Inhibitory Factor or Its Receptor (CD74) Attenuates Growth and Invasion of DU-145 Prostate Cancer Cells1 , 2006, The Journal of Immunology.

[11]  S. Kaufmann,et al.  Macrophage migration inhibitory factor (MIF) plays a pivotal role in immunity against Salmonella typhimurium , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Robert Kiss,et al.  Prognostic Values of Galectin-3 and the Macrophage Migration Inhibitory Factor (MIF) in Human Colorectal Cancers , 2003, Modern Pathology.

[13]  J. David,et al.  Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[14]  R. Koski,et al.  A Novel Allosteric Inhibitor of Macrophage Migration Inhibitory Factor (MIF)* , 2012, The Journal of Biological Chemistry.

[15]  J. Kyriakis.  Thinking Outside the Box about Ras* , 2009, Journal of Biological Chemistry.

[16]  J. Nishihira,et al.  Quantitation of macrophage migration inhibitory factor (MIF) using the one-step sandwich enzyme immunosorbent assay: elevated serum MIF concentrations in patients with autoimmune diseases and identification of MIF in erythrocytes. , 2000, International journal of molecular medicine.

[17]  T. Calandra,et al.  Macrophage migration inhibitory factor: a regulator of innate immunity , 2003, Nature Reviews Immunology.

[18]  H. Dosaka-akita,et al.  Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung , 2000, Cancer.

[19]  Elias Lolis,et al.  Direct link between cytokine activity and a catalytic site for macrophage migration inhibitory factor , 1998, The EMBO journal.

[20]  J. Swantek,et al.  Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK , 1997, Molecular and cellular biology.

[21]  R. Bucala,et al.  Macrophage migration inhibitory factor , 2003, Critical care medicine.

[22]  T. Straatsma,et al.  Internal dynamics and ionization states of the macrophage migration inhibitory factor: comparison between wild-type and mutant forms. , 2002, Biopolymers.

[23]  L. Leng,et al.  MIF Signal Transduction Initiated by Binding to CD74 , 2003, The Journal of experimental medicine.

[24]  J. Pouysségur,et al.  Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.

[25]  J. Bernhagen,et al.  Macrophage migration inhibitory factor (MIF): a promising biomarker. , 2010, Drug news & perspectives.

[26]  E. Morand,et al.  Is macrophage migration inhibitory factor a therapeutic target in systemic lupus erythematosus? , 2003, Immunology and cell biology.

[27]  E Lolis,et al.  Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity. , 1999, Biochemistry.

[28]  Javier Martín,et al.  Macrophage migration inhibitory factor gene: influence on rheumatoid arthritis susceptibility. , 2007, Human immunology.

[29]  G. Hannon,et al.  A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity , 1999, The Journal of experimental medicine.

[30]  R. Bucala,et al.  Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity by dopachrome analogs. , 1999, Bioorganic & medicinal chemistry letters.

[31]  E. Morand,et al.  Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase‐1 and p38 MAP kinase , 2006, FEBS letters.

[32]  C. Kozak,et al.  Conserved gene structure and genomic linkage for D-dopachrome tautomerase (DDT) and MIF , 1998, Mammalian Genome.

[33]  E. Briganti,et al.  Macrophage migration inhibitory factor in systemic lupus erythematosus. , 2004, The Journal of rheumatology.

[34]  L. Leng,et al.  CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. , 2006, Immunity.

[35]  J. Bernhagen,et al.  MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis , 2006, Nature Reviews Drug Discovery.

[36]  Zoe Cournia,et al.  Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. , 2009, Journal of medicinal chemistry.

[37]  J. Bernhagen,et al.  Link between macrophage migration inhibitory factor and cellular redox regulation. , 2005, Antioxidants & redox signaling.

[38]  R. Kleemann,et al.  Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. , 1998, Journal of molecular biology.

[39]  H. Lashuel,et al.  An integrative in silico methodology for the identification of modulators of macrophage migration inhibitory factor (MIF) tautomerase activity. , 2010, Bioorganic & medicinal chemistry.

[40]  M. Bennett,et al.  Endogenous p53 Protects Vascular Smooth Muscle Cells From Apoptosis and Reduces Atherosclerosis in ApoE Knockout Mice , 2004, Circulation research.

[41]  L. Tartaglia,et al.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.

[42]  L. Leng,et al.  Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart , 2008, Nature.

[43]  V. Tkachuk,et al.  Interleukin-18 and Macrophage Migration Inhibitory Factor Are Associated With Increased Carotid Intima–Media Thickening , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[44]  R. Bucala,et al.  Macrophage migration inhibitory factor: a probable link between inflammation and cancer. , 2007, Immunity.

[45]  R. Bucala,et al.  Macrophage migration inhibitory factor. , 2005, Critical care medicine.

[46]  C. P. Whitman.  The 4-oxalocrotonate tautomerase family of enzymes: How nature makes new enzymes using a β-α-β structural motif , 2002 .

[47]  Kirk W. Johnson,et al.  Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast , 2010, Proceedings of the National Academy of Sciences.

[48]  Peter Björk,et al.  The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase , 1997, FEBS letters.

[49]  J. Bernhagen,et al.  Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1 , 2000, Nature.

[50]  Lili Li,et al.  Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1. , 2006, Biochemical and biophysical research communications.

[51]  T. Lóránd,et al.  Macrophage migration inhibitory factor (MIF) tautomerase inhibitors as potential novel anti-inflammatory agents: current developments. , 2009, Current medicinal chemistry.

[52]  J. Bernhagen,et al.  Macrophage migration inhibitory factor: a noncanonical chemokine important in atherosclerosis. , 2009, Trends in cardiovascular medicine.

[53]  E. Morand,et al.  Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[54]  W. L. Jorgensen,et al.  Receptor agonists of macrophage migration inhibitory factor. , 2010, Bioorganic & medicinal chemistry letters.

[55]  J. Bernhagen,et al.  MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment , 2007, Nature Medicine.

[56]  Markus Zweckstetter,et al.  Identification and Characterization of Novel Classes of Macrophage Migration Inhibitory Factor (MIF) Inhibitors with Distinct Mechanisms of Action* , 2010, The Journal of Biological Chemistry.

[57]  S. Donnelly,et al.  Inflammation and cancer: macrophage migration inhibitory factor (MIF)—the potential missing link , 2010, QJM : monthly journal of the Association of Physicians.

[58]  E. Dahl,et al.  Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity , 2007, Oncogene.

[59]  J. Bernhagen,et al.  MIF as a glucocorticoid-induced modulator of cytokine production , 1995, Nature.

[60]  C. Meisinger,et al.  Effect of macrophage migration inhibitory factor (MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: results from the MONICA/KORA Augsburg Case–Cohort Study, 1984–2002 , 2008, Diabetologia.

[61]  I. Tanaka,et al.  Crystal structure of human D-dopachrome tautomerase, a homologue of macrophage migration inhibitory factor, at 1.54 A resolution. , 1999, Biochemistry.

[62]  John O Trent,et al.  A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. , 2008, Cancer research.

[63]  J. Wischhusen,et al.  Macrophage migration inhibitory factor expression in cervical cancer , 2010, Journal of Cancer Research and Clinical Oncology.

[64]  Shulin Zhuang,et al.  Some insights into the stereochemistry of inhibition of macrophage migration inhibitory factor with 2-fluoro-p-hydroxycinnamate and its analogues from molecular dynamics simulations. , 2005, Journal of medicinal chemistry.

[65]  M. Sánchez-Niño,et al.  The MIF receptor CD74 in diabetic podocyte injury. , 2009, Journal of the American Society of Nephrology : JASN.

[66]  O. Volpert,et al.  Migration Inhibitory Factor Mediates Angiogenesis via Mitogen-Activated Protein Kinase and Phosphatidylinositol Kinase , 2003, Circulation research.

[67]  A. Aljada,et al.  Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. , 2004, The Journal of clinical endocrinology and metabolism.

[68]  J. Bernhagen,et al.  Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor (MIF). , 2006, Atherosclerosis.

[69]  E. Anderson.  Hudson et al. , 1977 .

[70]  Lin Li,et al.  Understanding microscopic binding of macrophage migration inhibitory factor with phenolic hydrazones by molecular docking, molecular dynamics simulations and free energy calculations. , 2012, Molecular bioSystems.

[71]  Roy J. Vaz,et al.  Fragment screening of inhibitors for MIF tautomerase reveals a cryptic surface binding site. , 2010, Bioorganic & medicinal chemistry letters.

[72]  C. P. Whitman.  The 4-oxalocrotonate tautomerase family of enzymes: how nature makes new enzymes using a beta-alpha-beta structural motif. , 2002, Archives of biochemistry and biophysics.